Form 4: Cardiff Oncology's Chief Medical Officer Acquires 150,000 Stock Options

Fairooz Kabbinavar, Chief Medical Officer of Cardiff Oncology, reports the acquisition of 150,000 stock options on March 11, 2025.

Summary

• On March 13, 2025, Fairooz Kabbinavar, the Chief Medical Officer of Cardiff Oncology, filed a Form 4 with the SEC.
• The filing reports the acquisition of 150,000 stock options with an exercise price of $3.58 on March 11, 2025.
• These options vest over time, with 25% vesting on March 11, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• Following the reported transaction, Kabbinavar directly owns 780,008 shares of Cardiff Oncology common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which doesn't inherently indicate positive or negative news, but reflects standard compensation practices.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the Chief Medical Officer.

Key Dates